# Training Hematology and Oncology Fellows in Clinical Research

> **NIH NIH T32** · OHIO STATE UNIVERSITY · 2022 · $164,454

## Abstract

PROJECT SUMMARY
The objective of this Ohio State University postdoctoral clinical T32 training program entitled: “Training
Hematology and Oncology Fellows in Clinical Research” is to provide a state of the art clinical research training
experience, specifically for postdoctoral fellows in Hematology and Oncology with an M.D., D.O., or equivalent
degree who have demonstrated a firm commitment to patient oriented cancer research. The overriding goal of
this training program is to prepare Hematology and Oncology fellows in the OSU Divisions of Hematology and
Medical Oncology for academic careers in patient oriented clinical and translational cancer investigation.
Progress in cancer therapy and prevention requires strong collaborative efforts, and patient oriented physician
investigators provide a critical link with physician-scientists and basic scientists toward this goal. The recent
explosive growth of scientific discoveries and the increasing complexity of cancer clinical trials, particularly phase
I/II studies of novel therapeutic agents and regimens, make it imperative that trainees in Hematology/Oncology
acquire the proper training through appropriate mentoring, to prepare them for careers in clinical and translational
investigation. This T32 program will prepare fellowship trainees for productive academic careers by providing an
intellectually rigorous curriculum, strong mentoring and support from senior faculty, protected time for academic
training during fellowship, “hands on” experience in developing and writing clinical studies and research papers,
and ample opportunities to enhance their OSU experience with extramural programs and workshops sponsored
by the NCI or other professional academic organizations such as ASCO and ASH. The participating members
consist of the 2 Program Directors, Coordinating Committee members, Advisory Committee members, primary
mentors, and contributing faculty, who were chosen based on their prior track record of successful mentoring
and their demonstrated commitment to clinical and translational research. T32 fellows will commit for two years
of training. The strengths of the OSUCCC, primarily in the fields of cancer prevention and experimental
therapeutics, is the perfect environment to our planned success. Our T32 proposal is designed to foster and
ensure the development of fellowship trainees, who we will train to assume academic clinical research positions
as faculty members upon graduation. The T32 program is engineered to empower trainees to become
independent clinical and translational investigators. Trainees will have mandatory an elective training in various
settings, including the opportunity to obtain one or two master degrees; they will be required to create an
investigator initiated clinical study and will start its implementation during training; they will be required to apply
for funding for their own study through peer reviewed grant mechanisms; and they will be offered the opportunity
to netw...

## Key facts

- **NIH application ID:** 10434663
- **Project number:** 5T32CA247815-03
- **Recipient organization:** OHIO STATE UNIVERSITY
- **Principal Investigator:** Claire F. Verschraegen
- **Activity code:** T32 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $164,454
- **Award type:** 5
- **Project period:** 2020-07-01 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10434663

## Citation

> US National Institutes of Health, RePORTER application 10434663, Training Hematology and Oncology Fellows in Clinical Research (5T32CA247815-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10434663. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*